SORACE, CHIARA
 Distribuzione geografica
Continente #
AS - Asia 96
NA - Nord America 74
EU - Europa 61
SA - Sud America 6
AF - Africa 2
Totale 239
Nazione #
US - Stati Uniti d'America 69
SG - Singapore 42
IT - Italia 25
CN - Cina 21
HK - Hong Kong 9
RU - Federazione Russa 8
DE - Germania 6
NL - Olanda 6
FR - Francia 5
BD - Bangladesh 4
BR - Brasile 4
CA - Canada 4
GB - Regno Unito 4
IN - India 4
JP - Giappone 4
VN - Vietnam 4
AT - Austria 3
ID - Indonesia 2
PH - Filippine 2
CL - Cile 1
CO - Colombia 1
EG - Egitto 1
ES - Italia 1
FI - Finlandia 1
HN - Honduras 1
IR - Iran 1
JO - Giordania 1
LV - Lettonia 1
PK - Pakistan 1
SE - Svezia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 239
Città #
Singapore 25
San Jose 10
Hong Kong 9
Los Angeles 8
Beijing 6
Rome 6
Council Bluffs 5
Ashburn 4
New York 4
Tokyo 4
Chandigarh 3
Toronto 3
Berlin 2
Ho Chi Minh City 2
Louisville 2
Milan 2
Santa Clara 2
São Paulo 2
Xi'an 2
Amman 1
Amsterdam 1
Atlanta 1
Baltimore 1
Bastos 1
Bridgeport 1
Brooklyn 1
Buffalo 1
Cairo 1
Chengdu 1
Chicago 1
City of London 1
Columbus 1
Dallas 1
Elk Grove 1
Elk Grove Village 1
Frankfurt am Main 1
Genoa 1
Grand Rapids 1
Itatiba 1
Jakarta 1
Johannesburg 1
Karachi 1
Kebumen 1
Lappeenranta 1
Lauterbourg 1
London 1
Lucknow 1
Manchester 1
Manila 1
Montreal 1
North Bergen 1
Nuremberg 1
Paris 1
Pasto 1
Poplar 1
Redondo Beach 1
Riga 1
San Francisco 1
San Pedro Sula 1
Santiago 1
Stockholm 1
Tampa 1
Tehran 1
The Dalles 1
Tolentino 1
West Sacramento 1
Ürümqi 1
Totale 149
Nome #
Persistence of circulating CD169+monocytes and HLA-DR downregulation underline the immune response impairment in PASC individuals: the potential contribution of different COVID-19 pandemic waves 118
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study) 101
Clinical and laboratory parameters correlated to HDV undetectability after 48 weeks of bulevirtide 23
Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study) 14
Totale 256
Categoria #
all - tutte 1.870
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.870


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202420 0 0 0 8 1 2 1 0 4 0 4 0
2024/202560 2 3 14 6 2 7 4 5 6 4 5 2
2025/2026176 6 7 12 19 18 4 16 18 19 26 24 7
Totale 256